SCHEMBL26242811

SCHEMBL26242811

CCC(=O)c1sc(C)cc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.37
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
CYP3A4 P08684 1/20 0.36
PTGS1 P23219 1/20 0.36
DRD3 P35462 1/20 0.36
TP53 P04637 3/20 0.36
PKM P14618 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
HTT P42858 1/20 0.34
ALDH1A1 P00352 6/20 0.34
HPGD P15428 3/20 0.34
KDM4E B2RXH2 3/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27602779 0.84 GSK3B (0.47) ALOX15MEN1KMT2ACYP3A4PTGS1
SCHEMBL17077939 0.82 GSK3B (0.52) PKMNPSR1RXFP1SMN1; SMN2HTT
SCHEMBL2028240 0.76 ALOX15 (0.61) ALOX15MEN1KMT2ATP53PKM
SCHEMBL5104631 0.76 PKM (0.52) ALOX15MEN1KMT2APKMNPSR1
SCHEMBL102004 0.76 ALDH1A1 (0.40) ALOX15MEN1KMT2ACYP3A4PKM
SCHEMBL12195825 0.75 NPC1 (0.47) ALOX15MEN1KMT2APKMNPC1
SCHEMBL7965972 0.74 IKBKB (0.42) ALOX15MEN1KMT2ACYP3A4PKM
SCHEMBL3057931 0.74 PKM (0.37) ALOX15MEN1KMT2APKMNPSR1
SCHEMBL18719429 0.72 POLB (0.38) ALOX15MEN1KMT2ACYP3A4TP53
SCHEMBL2027674 0.71 MAPT (0.47) ALOX15MEN1KMT2ACYP3A4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285569-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X Design Therapeutics, Inc. 2023-09-14 US disclosed
US-9303034-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2016-04-05 US disclosed
US-20150175613-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES IRM LLC (BM) 2015-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175613-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES TYR, TBCA, MAPT ALOX15 169/4885MEN1 1170/4885KMT2A 2041/4885
US-20230285569-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X CYFIP2, TPX2, CYFIP1 ALOX15 3992/4885MEN1 3313/4885KMT2A 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.